Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NePathe

AstraZeneca AZ

AZ-Lilly start second pivotal trial of fast-tracked Alzheimer’s drug

AMARANTH could be first treatment to target underlying mechanism

Sanofi reception

Sanofi loses lead on diabetes combo IGlarLixi after FDA delay

FDA verdict on Novo Nordisk’s rival combo Xultophy due next month 

- PMLiVE

Portola rejection hands advantage to Boehringer’s Pradaxa

FDA’s ruling on reversal agent for NOACs unexpected

- PMLiVE

Teva gets EU nod for severe asthma drug Cinqaero

Once-monthly dose able to improve asthma control

- PMLiVE

J&J therapy for suicidal depressives ‘a breakthrough’, says FDA

Status granted to esketamine after phase II PeRSERVERe trial

Deal Watch July 2016

Real deals, real money and - for some - reality bites

Biogen Idec building

Eisai and Biogen plan phase III trials for Alzheimer’s drug

BACE inhibitor E2609 may offer new treatment option

- PMLiVE

Novo Nordisk’s Tresiba gaining ground in basal insulin market

Delivers $216m this year despite ICER's report of insufficient data to favour the drug over Sanofi's Lantus

- PMLiVE

Teva acquires Allergan’s generics operations in $38.8bn deal

Also discloses $500m agreement to purchase the Irish firm’s distribution business

Novartis Gehry Building

FDA deems ribociclib a breast cancer breakthrough

Novartis looks to catch-up with Pfizer’s Ibrance with early approval in the US

- PMLiVE

Defining value: has anyone asked the patient?

The real-world challenges patients face give them unique views on ‘value’

- PMLiVE

EMA suspends generic drugs on data integrity concerns

Reports by FDA and WHO find evidence of data manipulation by Semler Research Centre

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links